LACTOLOGY FOUNDATION

Bismuth subcitrate (ATC A02BX05) is considered compatible with breastfeeding, with negligible transfer into milk at usual oral doses, while systemic toxicity is mainly a concern with prolonged high exposure or pre‑existing renal impairment. During pregnancy, available human data are limited; inorganic bismuth itself appears low risk at therapeutic doses, but fixed combinations containing other potentially teratogenic or fetotoxic drugs (e.g. metronidazole, tetracycline) require case‑by‑case assessment.file+5

Pharmacology and indications

Bismuth subcitrate is an inorganic salt that reacts with gastric hydrochloric acid to form insoluble bismuth oxychloride and bismuth citrate, creating a protective layer over gastric and duodenal mucosa. It has three main actions: antacid, anti‑ulcer (cytoprotective), and local anti‑infective activity against gastrointestinal pathogens, notably Helicobacter pylori.pubmed.ncbi.nlm.nih+2

Clinically, colloidal bismuth subcitrate is used for short‑term treatment of gastric and duodenal ulcers, non‑ulcer dyspepsia and as part of combination regimens for H. pylori eradication. In some markets, it is also used off‑label for symptom relief in functional dyspepsia and to reduce relapse rates after ulcer healing.accessdata.fda+2

Toxicology

After oral administration, bismuth subcitrate is poorly absorbed; most of the dose remains in the gastrointestinal lumen and is excreted in feces. Systemic exposure to ionic bismuth is therefore low in individuals with normal gastrointestinal integrity and renal function.file+1

At therapeutic doses and recommended duration, adverse effects are usually mild and reversible, including darkening of stool and tongue, nausea, vomiting, and rarely mild neuropsychiatric symptoms. Serious toxicity (bismuth encephalopathy, bone and joint toxicity) has been described mainly with prolonged administration of high cumulative doses of bismuth salts, often over months, and in the presence of impaired renal clearance.mims+1

Because bismuth is renally eliminated, accumulation and toxicity are more likely in patients with significant renal impairment, and treatment in such patients requires dose limitation or avoidance. Concomitant use with other nephrotoxic or neurotoxic agents may theoretically increase risk, although robust interaction data are limited.truemeds+2

Pregnancy safety

Inorganic bismuth formed from bismuth subsalicylate appears to confer little or no fetal risk at normal doses, but pregnancy data for bismuth salts are sparse and do not allow precise quantification of teratogenic risk. For bismuth subsalicylate, concern focuses mainly on systemic salicylate exposure rather than on bismuth itself; because chronic salicylate exposure has been associated with fetal adverse effects, its use is usually restricted and cautious during pregnancy.doctorlib

For colloidal bismuth subcitrate and bismuth subcitrate potassium (e.g. in triple or quadruple H. pylori therapy with metronidazole and tetracycline), there are no robust controlled human or animal data specifically isolating the bismuth component. In such fixed combinations, overall pregnancy risk is determined predominantly by the co‑administered antibiotics (tetracycline being contraindicated in later pregnancy, metronidazole generally avoided in first trimester unless clearly indicated).doctorlib+1

In your local framework, the monograph labels bismuth subcitrate as FDA pregnancy category A, implying adequate human data showing no increased risk in the first trimester and no evidence of harm later in pregnancy. Given the heterogeneity of international classifications and limited specific data, it is prudent to follow national guidelines and to favor the lowest effective dose and shortest effective duration, especially in early organogenesis.chemm.hhs+3

Lactation safety

Bismuth subcitrate has a molecular weight around 328 kDa in its colloidal form, theoretically allowing some transfer into breast milk, but its systemic absorption from the maternal gut is minimal. Consequently, measurable concentrations of bismuth in breast milk are expected to be extremely low or below detection, and clinically relevant infant exposure is unlikely.e-lactation+2

Available expert lactation resources note an absence of documented adverse effects in breastfed infants and consider bismuth salts without salicylate (such as citrate) as compatible with breastfeeding, with no need to interrupt lactation at conventional doses and durations. Your local classification accordingly places bismuth subcitrate in toxico‑lactation Category I, “fully suitable for use during lactation”.e-lactation+1

Caution is warranted mainly for bismuth subsalicylate, where the salicylate moiety is systemically absorbed and excreted into milk, albeit at a low fraction of the maternal dose; some reviews therefore advise avoiding this specific salt in lactating women when safer alternatives are available. General breastfeeding advice applies: avoid unnecessary medication, use the lowest effective dose for the shortest period, and monitor the infant for changes in feeding, behavior or gastrointestinal function if maternal treatment is prolonged.mayoclinic+2

Practical recommendations for use in lactating and pregnant women

• In healthy lactating women, short‑term use of oral bismuth subcitrate at standard doses for dyspepsia or ulcer disease is acceptable without interruption of breastfeeding.pubmed.ncbi.nlm.nih+2
• Prefer non‑salicylate bismuth preparations (e.g. subcitrate) over subsalicylate when treating breastfeeding mothers, particularly if repeated or prolonged courses are anticipated.nus+2
• Avoid prolonged or high‑dose use, and avoid use in women with significant renal impairment because of the risk of systemic accumulation and neurotoxicity.mims+1
• During pregnancy, reserve bismuth‑containing regimens for clear indications, considering alternative acid‑suppressive therapies with more robust safety data when appropriate.ncbi.nlm.nih+2
• When bismuth subcitrate is part of combination H. pylori therapy in pregnant women, risk–benefit assessment should prioritize the safety profile of concomitant antibiotics, often leading to deferral of eradication therapy until after pregnancy where clinically feasible.accessdata.fda+1